NCT05307835View on ClinicalTrials.gov

Neoantigen Vaccine in Esophagus Cancer Patients Following Neoadjuvant Therapy and Surgical Resection

PHASE1RecruitingINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

December 2, 2021

Primary Completion Date

December 2, 2025

Study Completion Date

December 3, 2025

Conditions
Resectable Esophageal Cancer
Interventions
BIOLOGICAL

iNeo-Vac-P01

iNeo-Vac-P01 (peptides)： 4 x 300 mcg per peptide given on days 1, 4, 8, 15, 22, 52, and 82 for a total of 7 doses;

BIOLOGICAL

GM-CSF

4 x 40 mcg (total dose 160 mcg) given on days 1, 4, 8, 15, 22, 52, and 82 for a total of 7 doses

Trial Locations (1)

310000

RECRUITING

The Second Affiliated Hospital of Zhejiang University, Hangzhou

All Listed Sponsors
collaborator

Hangzhou Neoantigen Therapeutics Co., Ltd.

INDUSTRY

lead

Second Affiliated Hospital, School of Medicine, Zhejiang University

OTHER